semaglutide immunogenicity nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential PDB-101: Diabetes Mellitus: Diabetes Mellitus:

GLP-1 medications have also been associated with: Worsening of diabetic retinopathy Exacerbation of age-related macular degeneration Optic nerve complications, including NAION These risks dont mean you should stop taking your medication, but they do show why its important to have an eye exam before starting and regular follow-up exams while on treatment

Finally, if taste changes significantly affect your quality of life or mental wellbeing , don't hesitate to raise this with your healthcare team

Explore more: Read the news here: #DrugSafety #PharmaceuticalResearch #MedicalResearch To view or add a comment, sign in More solid PK data on drug retention and bioavailability of Paclitaxel in the Agent DCB

Educational only No protocols No purchase required Final Notes & Disclaimers The protocols described above are for information purposes only

C-ANCA recognizes and reduces PR3 proteolytic activity and can interfere with the PR3/A1AT bond